Cargando…

Long-term clinical outcomes of Chinese diabetic patients after coronary revascularization with drug-eluting stents: a retrospective comparative cohort study

BACKGROUND: Compared to bare-metal stent implantation, coronary drug-eluting stent (DES) implantation is more likely to reduce restenosis and the need for a subsequent repeat revascularization procedure. Diabetes increases the risk of coronary heart disease and the population of diabetic patients ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yanping, Liu, Jixuan, Du, Yupeng, Lei, Duan, Liu, Hongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761126/ https://www.ncbi.nlm.nih.gov/pubmed/36544638 http://dx.doi.org/10.21037/atm-22-4517

Ejemplares similares

Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents
por: Halpern, Michael T, et al.
Publicado: (2004)

Drug‐Eluting or Bare‐Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization
por: Piccolo, Raffaele, et al.
Publicado: (2021)

Incomplete revascularization in the drug eluting stent era permits meaningful long-term (12-78 months) outcomes in patients ≥ 75 years with acute coronary syndrome
por: Chen, Jie, et al.
Publicado: (2012)

Ultrathin Strut Biodegradable Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent for Percutaneous Coronary Revascularization: 2‐Year Results of the BIOSCIENCE Trial
por: Zbinden, Rainer, et al.
Publicado: (2016)

An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial
por: Zhang, Haijun, et al.
Publicado: (2019)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

Long-term effect of stents eluting 6-mercaptopurine in porcine coronary arteries
por: Ruiter, Matthijs S., et al.
Publicado: (2016)

Long-Term Outcomes of Complete Versus Incomplete Revascularization for Patients with Multivessel Coronary Artery Disease and Left Ventricular Systolic Dysfunction in Drug-Eluting Stent Era
por: Sohn, Gwan Hyeop, et al.
Publicado: (2014)

Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients
por: Chan, Pak-Hei, et al.
Publicado: (2013)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

Coronary stenting: A matter of revascularization
por: Bonaventura, Aldo, et al.
Publicado: (2017)

Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis
por: Meng, Min, et al.
Publicado: (2016)

Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease
por: Her, Ae-Young, et al.
Publicado: (2023)

“Burying” covered coronary stents under drug-eluting stents: A novel approach to ensure long-term stent patency
por: Bossard, Matthias, et al.
Publicado: (2023)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis
por: Zeng, MengYing, et al.
Publicado: (2021)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Sirolimus-eluting coronary stents: a review
por: Abizaid, Alexandre
Publicado: (2007)

Incidence, Predictors, and Outcomes of Acute and Sub-acute Stent Thrombosis after Emergency Percutaneous Coronary Revascularization with Drug-Eluting Stents: A Prospective Observational Study
por: Kumar, Rajesh, et al.
Publicado: (2022)

Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review
por: Sohail, Mehvish, et al.
Publicado: (2023)

Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2017)

Risk Factors for Long-term Outcome of Drug-eluting Stenting in Adults with Early-onset Coronary Artery Disease
por: An, Guipeng, et al.
Publicado: (2014)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions
por: Fam, Jiang Ming, et al.
Publicado: (2017)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas, Vasileios F, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
por: Ahmed, Talha, et al.
Publicado: (2022)

Trial sequential analysis of studies comparing the frequency of target-vessel revascularization with drug-coated balloons as compared with second-generation drug-eluting stents in coronary in-stent restenosis: Have we generated enough evidence in the field?
por: Kumar, Ashish, et al.
Publicado: (2019)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Five-year comparative study of thin-strut rapamycin-eluting bioabsorbable scaffold with metallic drug-eluting stent in porcine coronary artery
por: Liu, Yaokun, et al.
Publicado: (2022)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina, Mahesh, et al.
Publicado: (2011)

Long-term Clinical Outcomes of Drug-Eluting Stent Malapposition
por: Lee, Seung-Yul, et al.
Publicado: (2020)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b98c3nfqm5t9krd1kue2s65mlt